Skip to main content

-

RYC-2012-10651

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Contratación e Incorporación de RRHH
Subprogram Subprograma Ramón y Cajal (RYC)
Call Ramón y Cajal
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1

  • Cifdaloz, Metehan
  • Osterloh, Lisa
  • Graña-Castro, Osvaldo
  • Riveiro-Falkenbach, Erica
  • Ximénez-Embún, Pilar
  • Muñoz, Javier
  • Tejedo, Cristina
  • Calvo, Tonantzin G.
  • Karras, Panagiotis
  • Olmeda, David
  • Miñana Gómez, Belén
  • Gómez López, Gonzalo
  • Cañón, Estela
  • Eyras Jiménez, Eduardo
  • Guo, Haihong
  • Kappes, Ferdinand
  • Ortíz Romero, Pablo Luis
  • Rodríguez Peraltó, José Luís
  • Megías, Diego
  • Valcárcel, J. (Juan)
  • Soengas, María S.
Melanomas are well-known for their altered mRNA expression profiles. Yet, the specific contribution of mRNA binding proteins (mRBPs) to melanoma development remains unclear. Here we identify a cluster of melanoma-enriched genes under the control of CUGBP Elav-like family member 1 (CELF1). CELF1 was discovered with a distinct prognostic value in melanoma after mining the genomic landscape of the 692 known mRBPs across different cancer types. Genome-wide transcriptomic, proteomic, and RNA-immunoprecipitation studies, together with loss-of-function analyses in cell lines, and histopathological evaluation in clinical biopsies, revealed an intricate repertoire of CELF1-RNA interactors with minimal overlap with other malignancies. This systems approach uncovered the oncogene DEK as an unexpected target and downstream effector of CELF1. Importantly, CELF1 and DEK were found to represent early-induced melanoma genes and adverse indicators of overall patient survival. These results underscore novel roles of CELF1 in melanoma, illustrating tumor type-restricted functions of RBPs in cancer., M.S.S. was funded by Marató TVE, Consolider RNAREG (CSD2009-00080), and SAF2014-56868-R (Spanish Ministry of Economy and Innovation). J.V. was funded by Fundación Botín, Banco de Santander through its Santander Universities Global Division, Consolider RNAREG (CSD2009-00080), AGAUR and the European Research Council, and acknowledges support of the Spanish Ministry of Economy and Competitiveness, Centro de Excelencia Severo Ochoa 2013-2017. J.L.R.-P. was funded by grant FIS 2014/1737, and P.L.O.-R. by FIS 14/1784 from the Spanish Ministry of Health. E.E. was funded by grants BIO2011-23920, Consolider RNAREG (CSD2009-00080), by AGAUR (2014-SGR1121) and by the Sandra Ibarra Foundation for Cancer (FSI2013). The CNIO Proteomics Unit belongs to ProteoRed, PRB2- ISCIII, supported by grant PT13/0001. J.M. was supported by the Ramon y Cajal Programme (MINECO) RYC-2012-10651. H.G. and F.K. were funded by the China Scholarship Council, the Deutsche Forschungsgemeinschaft (DFG KA 2799/1) and the START Program of the Faculty of Medicine of the RWTH Aachen University. M.C. and P.K. were funded by predoctoral fellowships from Fundación La Caixa, and C.T. from SAF2014-56868-R. E.R.-F. was a recipient of a postdoctoral fellowship from “Fundación Científica de la Asociación Española Contra el Cáncer” and was also supported by FMM-2013/0075 of Fundacion Mutua Madrileña.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

  • Cerezo-Wallis, Daniela
  • Contreras-Alcalde, Marta
  • Troulé, Kevin
  • Catena, Xavier
  • Mucientes, Cynthia
  • Calvo, Tonantzin G.
  • Cañón, Estela
  • Tejedo, Cristina
  • Pennacchi, Paula C.
  • Hogan , Sabrina
  • Kölblinger, Peter
  • Tejero, Héctor
  • Chen, Andrew X.
  • Ibarz, Nuria
  • Graña, Osvaldo
  • Martinez, Lola
  • Muñoz, Javier
  • Ortiz-Romero, Pablo
  • Rodríguez-Peralto, José L.
  • Gómez-López, Gonzalo
  • Al-Shahrour, Fátima
  • Rabadán, Raúl
  • Levesque, Mitchell P.
  • Olmeda, David
  • Soengas, María S.
An open question in aggressive cancers such as melanoma is how malignant cells can shift the immune system to pro-tumorigenic functions. Here we identify midkine (MDK) as a melanoma-secreted driver of an inflamed, but immune evasive, microenvironment that defines poor patient prognosis and resistance to immune checkpoint blockade. Mechanistically, MDK was found to control the transcriptome of melanoma cells, allowing for coordinated activation of nuclear factor-κB and downregulation of interferon-associated pathways. The resulting MDK-modulated secretome educated macrophages towards tolerant phenotypes that promoted CD8+ T cell dysfunction. In contrast, genetic targeting of MDK sensitized melanoma cells to anti-PD-1/ anti-PD-L1 treatment. Emphasizing the translational relevance of these findings, the expression profile of MDK-depleted tumors was enriched in key indicators of a good response to immune checkpoint blockers in independent patient cohorts. Together, these data reveal that MDK acts as an internal modulator of autocrine and paracrine signals that maintain immune suppression in aggressive melanomas., M.S.S. is funded by grants from the Spanish Ministry of Economy and Innovation (SAF2017-89533-R), Team Science and Established Investigator awards by the Melanoma Research Alliance, and grants from Worldwide Cancer Research and Fundación ‘La Caixa’ Health Research 2019. M.S.S., P.O.-R. and J.L.R.-P. are funded by a collaborative grant from the Asociación Española Contra el Cáncer (AECC). D.O. is funded by grants from the Spanish Ministry of Health (AES-PIS PI18/1057) and ‘Fundación BBVA-Becas Leonardo a Investigadores y Creadores Culturales 2018’. D.C.-W. was a recipient of a predoctoral fellowship from Fundación ‘La Caixa’ and is currently funded by the AECC. The CNIO Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001. N.I. and J.M. are funded by SAF2013-45504-R (MINECO). J.M. is also supported by Ramón y Cajal Programme (MINECO) RYC-2012-10651. M.C.-A. and X.C. were funded by the Immutrain Marie Skłodowska-Curie ITN Grant. S.H. received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement number 641458., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors

  • Karras, Panagiotis
  • Riveiro-Falkenbach, Erica
  • Cañón, Estela
  • Tejedo, Cristina
  • Calvo, Tonantzin G.
  • Martínez-Herranz, Raúl
  • Alonso-Curbelo, Direna
  • Cifdaloz, Metehan
  • Pérez-Guijarro, Eva
  • Gómez-López, Gonzalo
  • Ximénez-Embún, P.
  • Muñoz, Javier
  • Megías, Diego
  • Olmeda, David
  • Moscat, Jorge
  • Ortiz-Romero, Pablo
  • Rodríguez-Peralto, José L.
  • Soengas, María S.
Modulators of mRNA stability are not well understood in melanoma, an aggressive tumor with complex changes in the transcriptome. Here we report the ability of p62/SQSTM1 to extend mRNA half-life of a spectrum of pro-metastatic factors. These include FERMT2 and other transcripts with no previous links to melanoma. Transcriptomic, proteomic, and interactomic analyses, combined with validation in clinical biopsies and mouse models, identified a selected set of RNA-binding proteins (RBPs) recruited by p62, with IGF2BP1 as a key partner. This p62-RBP interaction distinguishes melanoma from other tumors where p62 controls autophagy or oxidative stress. The relevance of these data is emphasized by follow-up analyses of patient prognosis revealing p62 and FERMT2 as adverse determinants of disease-free survival., M.S.S. is funded by grants from the Spanish Ministry of Economy and Innovation (SAF2014-56868-R; SAF2017-89533-R), the Asociación Española Contra el Cáncer (AECC), TV’13-20131430 (Marato de TV3), the Worldwide Cancer Research, an Established Investigator Award by the Melanoma Research Alliance (MRA), and a L'Oreal-Paris USA-MRA Team Science Award for Women in Scientific Research. M.S.S. also acknowledges a donation from “Fundación Causa Alexandra”, Spain. P.K. was a recipient of a predoctoral fellowship from Fundación La Caixa. E.R.-F. was funded by Fundación Mutua Madrileña (FMM-2013) and was a recipient of a fellowship from ‘‘Fundación Científica de la Asociación Española Contra el Cáncer”. The CNIO Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001. J.M. is also supported by Ramon y Cajal Programme (MINECO) RYC-2012-10651. J.L.R.-P. is funded by FIS 2014/173711/02568 and CIBERONC, and P.L.O.-R. by FIS 11/17592014/01784, from the Spanish Ministry of Health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets

  • Hurtado, Begoña
  • Trakala, Marianna
  • Ximénez-Embún, Pilar
  • El Bakkali, Aicha
  • Partida, David
  • Sanz-Castillo, Belén
  • Álvarez-Fernández, Mónica
  • Maroto, María
  • Sánchez-Martínez, Ruth
  • Martínez, Lola
  • Redondo-Muñoz, Javier
  • García de Frutos, Pablo
  • Malumbres, Marcos
MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated in autosomal dominant thrombocytopenia. However, the connections between the cell-cycle machinery and this human disease remain unexplored. We report here that, whereas Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a consequence of aberrant activation and survival of platelets. Activation of mutant platelets was characterized by hyperstabilized pseudopods mimicking the effect of PP2A inhibition and actin polymerization defects. These aberrations were accompanied by abnormal hyperphosphorylation of multiple components of the actin cytoskeleton and were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC, or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeletal dynamics in postmitotic cells and suggest that the thrombocytopenia-associated mutation in MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity resulting in altered phosphorylation of cytoskeletal regulatory pathways., BH and RSM were supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (MINECO). MT was supported by the Foundation La Caixa. AEB was supported by the Programa de Empleo Juvenil, Comunidad de Madrid. MAF received a young investigator grant from MINECO (SAF2014-60442-JIN, cofinanced by FEDER funds). PGDF was supported by the Fundació la Marató de TV3 (projects 080121 and 20153031). JM was supported by the Ramon y Cajal Programme (MINECO; RYC-2012-10651). The laboratory of MM is supported by grants from MINECO (SAF2015-69920-R); the Programa iLUNG from the Comunidad de Madrid (B2017/BMD-3884); and Worldwide Cancer Research (15-0278). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1

  • Cifdaloz, Metehan
  • Osterloh, Lisa
  • Graña-Castro, Osvaldo
  • Riveiro-Falkenbach, Erica
  • Ximénez-Embún, Pilar
  • Muñoz, Javier
  • Tejedo, Cristina
  • Calvo, Tonantzin G.
  • Karras, Panagiotis
  • Olmeda, David
  • Miñana Gómez, Belén
  • Gómez López, Gonzalo
  • Cañón, Estela
  • Eyras Jiménez, Eduardo
  • Guo, Haihong
  • Kappes, Ferdinand
  • Ortíz Romero, Pablo Luis
  • Rodríguez Peraltó, José Luís
  • Megías, Diego
  • Valcárcel, J. (Juan)
  • Soengas, María S.
Melanomas are well-known for their altered mRNA expression profiles. Yet, the specific contribution of mRNA binding proteins (mRBPs) to melanoma development remains unclear. Here we identify a cluster of melanoma-enriched genes under the control of CUGBP Elav-like family member 1 (CELF1). CELF1 was discovered with a distinct prognostic value in melanoma after mining the genomic landscape of the 692 known mRBPs across different cancer types. Genome-wide transcriptomic, proteomic, and RNA-immunoprecipitation studies, together with loss-of-function analyses in cell lines, and histopathological evaluation in clinical biopsies, revealed an intricate repertoire of CELF1-RNA interactors with minimal overlap with other malignancies. This systems approach uncovered the oncogene DEK as an unexpected target and downstream effector of CELF1. Importantly, CELF1 and DEK were found to represent early-induced melanoma genes and adverse indicators of overall patient survival. These results underscore novel roles of CELF1 in melanoma, illustrating tumor type-restricted functions of RBPs in cancer., M.S.S. was funded by Marató TVE, Consolider RNAREG (CSD2009-00080), and SAF2014-56868-R (Spanish Ministry of Economy and Innovation). J.V. was funded by Fundación Botín, Banco de Santander through its Santander Universities Global Division, Consolider RNAREG (CSD2009-00080), AGAUR and the European Research Council, and acknowledges support of the Spanish Ministry of Economy and Competitiveness, Centro de Excelencia Severo Ochoa 2013-2017. J.L.R.-P. was funded by grant FIS 2014/1737, and P.L.O.-R. by FIS 14/1784 from the Spanish Ministry of Health. E.E. was funded by grants BIO2011-23920, Consolider RNAREG (CSD2009-00080), by AGAUR (2014-SGR1121) and by the Sandra Ibarra Foundation for Cancer (FSI2013). The CNIO Proteomics Unit belongs to ProteoRed, PRB2- ISCIII, supported by grant PT13/0001. J.M. was supported by the Ramon y Cajal Programme (MINECO) RYC-2012-10651. H.G. and F.K. were funded by the China Scholarship Council, the Deutsche Forschungsgemeinschaft (DFG KA 2799/1) and the START Program of the Faculty of Medicine of the RWTH Aachen University. M.C. and P.K. were funded by predoctoral fellowships from Fundación La Caixa, and C.T. from SAF2014-56868-R. E.R.-F. was a recipient of a postdoctoral fellowship from “Fundación Científica de la Asociación Española Contra el Cáncer” and was also supported by FMM-2013/0075 of Fundacion Mutua Madrileña.